Physician profile
David N Baker
NPI 1962583740
$36,886.35
in general payments reported to CMS, 2019-2025
72 companies · $8,650 in 2025
The $8,650 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,869 · 2022: $5,778 · 2023: $3,406 · 2024: $9,184 · 2025: $8,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $3,235 · Travel and Lodging: $1,768 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,525 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,530.71 |
| Consulting Fee | $3,235.00 |
| Travel and Lodging | $1,768.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,525.00 |
| Education | $181.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,146.36 | 2021-2025 | |
| Abbvie INC. | $2,636.36 | 2021-2025 | |
| Pfizer INC. | $1,996.13 | 2021-2025 | |
| Allergan, INC. | $1,928.82 | 2021-2022 | |
| Biogen, INC. | $1,717.08 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,590.08 | 2021-2025 | Fintepla, Briviact, Rystiggo |
| Sk Life Science, INC. | $1,462.03 | 2021-2025 | Xcopri |
| Ipsen Pharma Sas | $1,418.12 | 2022 | |
| Ipsen Innovation | $1,174.48 | 2025 | |
| Amgen INC. | $1,095.05 | 2021-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $984.73 | 2021-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $966.54 | 2021-2025 | Gocovri, Gocovri, Qelbree |
| Ani Pharmaceuticals, INC. | $963.40 | 2022-2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $867.00 | 2021-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $862.18 | 2021-2025 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $818.73 | 2021-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $674.22 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurelis, INC. | $614.55 | 2021-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $613.51 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $543.58 | 2025 | Symbravo, Auvelity |
| Acadia Pharmaceuticals INC | $521.66 | 2021-2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $500.83 | 2021-2025 | Hyqvia, Gammagard, Trintellix |
| Amneal Pharmaceuticals LLC | $480.51 | 2021-2025 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Mallinckrodt Hospital Products INC. | $480.23 | 2021-2025 | Acthar |
| Genentech USA, INC. | $463.60 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $435.52 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Kyowa Kirin, INC. | $378.51 | 2021-2024 | Nourianz |
| Banner Life Sciences, LLC | $343.86 | 2021-2024 | |
| Csl Behring | $325.75 | 2021-2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $273.61 | 2021-2025 | Xeomin, Inbrija |
| Biohaven Pharmaceuticals, INC. | $268.26 | 2021 | |
| Harmony Biosciences LLC | $253.87 | 2021-2025 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $251.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $246.40 | 2021-2022 | |
| Janssen Biotech, INC. | $243.19 | 2025 | |
| Supernus Pharmaceuticals, INC. | $234.03 | 2021-2022 | |
| Celgene Corporation | $218.98 | 2021-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $196.07 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $193.38 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $172.17 | 2022 | |
| Horizon Therapeutics Plc | $138.29 | 2021-2023 | Uplizna |
| Octapharma USA, INC. | $134.10 | 2023-2025 | Panzyga |
| Ge Healthcare | $131.53 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $122.88 | 2024-2025 | Ponvory |
| Lilly USA, LLC | $121.20 | 2021-2024 | Amyvid, Emgality |
| Ipsen Biopharmaceuticals, INC | $114.29 | 2021-2025 | Dysport, Sohonos |
| Catalyst Pharmaceuticals, INC. | $109.94 | 2021-2024 | Fycompa |
| Virtus Pharmaceuticals LLC | $106.54 | 2025 | Levorphanol Tartrate |
| Tg Therapeutics, INC. | $102.45 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.04 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $101.78 | 2021 | |
| Medtronic, INC. | $97.54 | 2022 | |
| Sumitomo Pharma America, INC. | $95.41 | 2023-2024 | Aptiom |
| Acorda Therapeutics, INC | $93.63 | 2021-2023 | Inbrija |
| Genzyme Corporation | $81.74 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.77 | 2023-2024 | Nuedexta, Rexulti |
| Alnylam Pharmaceuticals INC. | $70.08 | 2021-2025 | Amvuttra |
| Scilex Pharmaceuticals INC. | $62.98 | 2022-2024 | |
| Avanir Pharmaceuticals, INC. | $62.23 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $59.46 | 2021 | |
| Zogenix INC. | $55.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.92 | 2021 | |
| Grifols USA, LLC | $39.93 | 2022-2025 | Gamunex-C |
| Upsher-Smith Laboratories LLC | $35.86 | 2021-2023 | |
| Azurity Pharmaceuticals, INC. | $35.71 | 2024 | Horizant |
| Aucta Pharmaceuticals, INC. | $26.60 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $26.09 | 2025 | Bafiertam, Tascenso Odt |
| Livanova USA, INC. | $23.95 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Edwards Lifesciences Corporation | $17.38 | 2021 | |
| Abbott Laboratories | $17.03 | 2024 | Proclaim |
| Nevro Corp. | $14.98 | 2022 | |
| Life Molecular Imaging LTD | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.